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IMPORTANCE Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is
causally associated with the risk of coronary heart disease (CHD), but randomized trials of
several therapies that reduce Lp(a) levels by 25% to 35% have not provided any evidence
that lowering Lp(a) level reduces CHD risk.
OBJECTIVE To estimate themagnitude of the change in plasma Lp(a) levels needed to have
the same evidence of an association with CHD risk as a 38.67-mg/dL (ie, 1-mmol/L) change in
low-density lipoprotein cholesterol (LDL-C) level, a change that has been shown to produce a
clinically meaningful reduction in the risk of CHD.
DESIGN, SETTING, AND PARTICIPANTS Amendelian randomization analysis was conducted
using individual participant data from 5 studies and with external validation using
summarized data from 48 studies. Population-based prospective cohort and case-control
studies featured 20 793 individuals with CHD and 27 540 controls with individual participant
data, whereas summarized data included 62 240 patients with CHD and 127 299 controls.
Data were analyzed fromNovember 2016 toMarch 2018.
EXPOSURES Genetic LPA score and plasma Lp(a) mass concentration.
MAINOUTCOMES ANDMEASURES Coronary heart disease.
RESULTS Of the included study participants, 53%weremen, all were of white European
ancestry, and themean age was 57.5 years. The association of genetically predicted Lp(a) with
CHD risk was linearly proportional to the absolute change in Lp(a) concentration. A 10-mg/dL
lower genetically predicted Lp(a) concentration was associated with a 5.8% lower CHD risk
(odds ratio [OR], 0.942; 95% CI, 0.933-0.951; P = 3 × 10−37), whereas a 10-mg/dL lower
genetically predicted LDL-C level estimated using an LDL-C genetic score was associated with
a 14.5% lower CHD risk (OR, 0.855; 95% CI, 0.818-0.893; P = 2 × 10−12). Thus, a 101.5-mg/dL
change (95% CI, 71.0-137.0) in Lp(a) concentration had the same association with CHD risk as
a 38.67-mg/dL change in LDL-C level. The association of genetically predicted Lp(a)
concentration with CHD risk appeared to be independent of changes in LDL-C level owing to
genetic variants that mimic the relationship of statins, PCSK9 inhibitors, and ezetimibe with
CHD risk.
CONCLUSIONS AND RELEVANCE The clinical benefit of lowering Lp(a) is likely to be
proportional to the absolute reduction in Lp(a) concentration. Large absolute reductions in
Lp(a) of approximately 100mg/dLmay be required to produce a clinically meaningful
reduction in the risk of CHD similar in magnitude to what can be achieved by lowering LDL-C
level by 38.67mg/dL (ie, 1 mmol/L).
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A polipoprotein(a), which is encoded by the LPA gene,covalently binds to a cholesterol-rich low-densitylipoprotein (LDL)particle to formlipoprotein(a) (Lp[a]).1
Meta-analyses of prospective observational studies have re-
ported that higher plasma Lp(a) concentration is associated
with dose-dependent higher risk of coronary heart disease
(CHD).2Furthermore,mendelian randomizationanalyseshave
provided strong evidence that the association between Lp(a)
and risk of CHD is likely to be causal.3-5However, several large
randomized trials evaluating therapies that lower Lp(a) con-
centration by between 20% and 35% (including niacin, cho-
lesterol ester transfer protein inhibitors, and PCSK9 inhibi-
tors) have not provided clear evidence that lowering plasma
Lp(a) concentration reduces the risk of cardiovascular events
beyond that which would be expected from the observed
LDL-loweringeffectof these therapies.6-11Althoughthese trials
werenot specifically designed to assess theLp(a)-lowering ef-
fectof theseagents, these trials raise thequestionofhowmuch
Lp(a) concentration must be lowered to produce a clinically
meaningful reduction in cardiovascular events.Therapies that
more specifically and potently lower Lp(a) concentrations by
up to 90% by inhibiting apolipoprotein(a) synthesis are in
development.12 Whether lowering Lp(a) concentrations with
these new therapies will reduce the risk of cardiovascular
events is unknown.
Owing to the skeweddistributionof plasmaLp(a) concen-
tration, prior studies have reported the association between
log-transformed concentrations of Lp(a) and CHD risk.2,13-15
Changes in log-transformed Lp(a) concentrations represent
proportional changes in Lp(a) concentrations. However, pro-
portional reduction is not ausefulmetric for assessing thepo-
tential clinical benefit of loweringLp(a) level because concen-
trations can vary by asmuch as 1000-fold amongmembers of
the same population, and therefore, the same proportional
change in Lp(a) concentration can result in markedly dif-
ferent absolute changes, depending on the initial Lp(a)
concentration.16
Importantly, statins and other therapies that reduce LDL
particle concentrations are associated with a dose-
dependent reduction in the risk of cardiovascular events that
is determined by the absolute (rather than the proportional)
change inLDLcholesterol (LDL-C) level.17-19BecauseLp(a) con-
tainsanLDLparticle,wehypothesized that therewouldbeevi-
dence to support a clinical association of Lp(a) with the risk
of CHD that may also be proportional to the absolute change
in circulating Lp(a) mass concentration. To test this hypoth-
esis,we created agenetic score to estimate themagnitude and
shapeof the relationshipofLp(a)with the riskofCHD.We then
estimated the absolute change in plasma Lp(a) concentration
required to achieve the equivalent change in CHD risk as a
38.67-mg/dL (ie, 1-mmol/L) change in LDL-C level (to convert
tomillimoles per liter,multiply by0.0259), a change inLDL-C
that has been demonstrated to produce a clinically meaning-
ful 20% to 25% reduction in the risk of cardiovascular events
in short-term trials.17-19 Our objectivewas tomake inferences
about howmuch Lp(a) concentration must be reduced phar-
macologically to produce a clinicallymeaningful reduction in
CHD risk and thereby determinewho ismost likely to benefit
from treatment with Lp(a)-lowering therapy to inform clini-
cal guidelines and the design of randomized trials evaluating
Lp(a)-lowering therapies.
Methods
Study Population andOutcomes
We studied 48333 participants of European descent (includ-
ing 20 793 with CHD) from 5 studies for whom individual
participant–level data were available as part of the CHD
Exome+ Consortium. Descriptions of the included studies are
provided in eMethods 1 of the Supplement. The primary out-
come was CHD, defined as CHD death, nonfatal myocardial
infarction, or (for 3 of the studies) other coronary events with
International Statistical Classification of Diseases and Related
Health Problems, Tenth Revision codes I20-25. Participants
provided written informed consent for genetic studies. As
this was an analysis of anonymized data that had already
been collected, ethical approval was not sought for this par-
ticular investigation.
LPAGenetic Score
All CHD Exome+ Consortium participants were genotyped
using a customized version of the Illumina Exome Beadchip
array, which included ultrafine mapping of the LPA gene re-
gion involving 2426variants genotypedwithin a 660-kbwin-
dow (eFigure 1 in the Supplement). To select variants for in-
clusion in the genetic score, we identified variants in the LPA
gene region thatwere conditionally associatedwithLp(a) con-
centrationsatagenome-wide levelof significance (P < 5 × 10−8)
usingforwardstepwiseregressionamongparticipants free from
CHDat baseline in each study.Weadjusted for study, age, sex,
and 5principal components of ancestry. Genetic variants cor-
related with a selected variant at r2 greater than 0.4 were ex-
cluded from further steps of the procedure (eFigure 2 in the
Supplement). For each participant, we calculated a weighted
genetic score by summing the number of Lp(a)-raising alleles
inherited at each variant included in the score, weighted by
each variant’s associationwith absolute change in Lp(a)mass
Key Points
Question Howmuch does plasma lipoprotein(a) need to be
lowered to produce a clinically meaningful reduction in the risk of
coronary heart disease?
Findings In a mendelian randomization analysis involving more
than 80000 patients andmore than 150000 controls, coronary
heart disease risk was proportionally associated with the absolute
change in plasma lipoprotein(a) mass concentration;
a 101.5-mg/dL change in lipoprotein(a) concentration was
associated with the same coronary heart disease risk as a
38.67-mg/dL (ie, 1-mmol/L) change in low-density lipoprotein
cholesterol level.
Meaning Lipoprotein(a) concentrationmust be lowered by
approximately 100mg/dL to achieve the same reduction in
coronary heart disease risk as can be achieved by lowering
low-density lipoprotein cholesterol level by 38.67mg/dL.
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concentration (measured in milligrams per deciliter). In sen-
sitivity analyses, we repeated the primary analyses using dif-
ferent choices of variants in the genetic scores, as described
in eMethods 2 in the Supplement.
Study Design
To assess the dose-response shape of the association be-
tweengeneticallypredictedLp(a)andCHDrisk,wedividedpar-
ticipants intodeciles of thegenetic score andmeasured theas-
sociation between each decile of genetically predicted Lp(a)
concentration and the risk of CHDusing the first decile as the
reference group. Informedby the shapeof the association,we
estimated the association between the LPA score and the risk
of CHD for absolute changes in Lp(a) concentration.
To estimate the absolute reduction in Lp(a) concentra-
tion required to have the same change in CHD risk as a 38.67-
mg/dL decrease in LDL-C level, we used the following proto-
col (eFigure 3 in the Supplement). First, we measured the
association between theLPA score and the risk of CHDper 10-
mg/dL decrease in genetically predicted Lp(a) concentration.
Next, we measured the association between a genetic score
consisting of variants in or near genes that encode the targets
of currently available LDL-C–lowering therapies andCHD risk
per 10-mg/dLdecrease in genetically predictedLDL-C (eTable
1 in the Supplement).20We then calculated the ratio between
these 2 estimates to obtain the change in Lp(a) concentration
that has an equivalent associationwith CHD risk as a 1-mg/dL
change in LDL-C level. To estimate the amount Lp(a) concen-
trationmustbe reduced tohave thesameassociationwithCHD
risk as a 38.67-mg/dL reduction in LDL-C level, wemultiplied
this ratio by 38.67. Finally, we estimated the predicted short-
termchange associatedwithdifferentmagnitudesof pharma-
cological lowering of Lp(a) concentration by converting the
change inLp(a) concentration intoachange inLDL-C levelhav-
ing an equivalent predicted effect on CHD risk and using the
estimated change associatedwith statin treatment per 38.67-
mg/dL reduction in LDL-C level, as reported by the Choles-
terol Treatment Trialists’ Collaboration.17
Statistical Analyses
We estimated the association of each variant with Lp(a) or
LDL-Cconcentrationusing linear regressionandwithCHDrisk
using logistic regression. All regression analyses were per-
formedseparately ineachof the studies, adjusting for age, sex,
and the first 5 principal components of ancestry; these esti-
mates were combined across studies in a fixed-effects in-
verse variance-weighted meta-analysis. Heterogeneity was
assessed using the I2 statistic.Mendelian randomization esti-
mates were then obtained from these variant-specific esti-
mates using a previously reported method that accounts for
correlation between variants.21 Nonlinearity in the mende-
lian randomization estimates of the shape of the association
of Lp(a) change with the risk of CHDwas assessed using frac-
tionalpolynomials, asdescribedelsewhere.22Forexternal rep-
lication in an independent sample, we performed the same
analysesusing summarizedgenetic associationswithCHDrisk
from the Coronary Artery Disease GenomeWide Replication
andMeta-analysis (CARDIOGRAM) plus The Coronary Artery
Disease (C4D) Genetics (CARDIOGRAMplusC4D) consortium
in up to 62240 patients and 127 299 controls.23
All analyses were performed using the statistical soft-
wareplatformRversion 3.4.1 (RProgramming). Adetailedde-
scription of the methods is provided in eMethods 2 of the
Supplement.
Results
Participant Characteristics
The baseline characteristics of participants are presented in
Table 1. Across the 5 studies contributing to the initial sample,
themedianLp(a) concentrationvaried from13.6mg/dL to43.3
mg/dL (eTable 2 and eFigure 4 in the Supplement).
LPAGenetic Score
The stepwise selection procedure identified 43 genetic vari-
antsconditionallyassociatedwithLp(a) (eTable3 in theSupple-
ment). The genetic score comprising these variants ex-
plained 51% to 63% of the variance in Lp(a) concentration in
each study (eFigure 5 in the Supplement). This explanatory
ability is lower than observed previously24 because our ge-
netic score was constructed conservatively to minimize bias
owing to overfitting. Associations of each variant with Lp(a)
concentration and CHD risk are displayed in Figure 1.
Association of LPAGenetic ScoreWith CHD
In analyses dividing thepopulation into deciles of genetically
predicted absolute Lp(a) mass concentration, the exposure–
Table 1. Baseline Characteristics of Participants
Source No.
Patients With CHD,
No.
Lp(a) Measured,
No.a
Age, Mean (SD),
y Men, No.
Lp(a) Concentration, mg/dL
Mean (SD) Median
CCHS 7808 1943 7396 58 (15) 3463 29.3 (33.6) 16.9
CGPS-CIHDS 17 120 7740 9964 59 (13) 9635 25.0 (28.1) 13.6
EPIC-CVD 20 780 9810 15 899 55 (10) 9792 52.6 (37.1) 43.3
PROSPER 1279 641 0 76 (4) 708 NA NA
WOSCOPS 1346 659 1017 56 (6) 1346 36.0 (39.3) 19.0
Abbreviations: CCHS, Copenhagen City Heart study; CGPS, Copenhagen
General Population study; CHD, coronary heart disease; CIHDS, Copenhagen
Ischemic Heart Disease study; EPIC-CVD, European Prospective Investigation
Into Cancer and Nutrition-Cardiovascular Disease study; Lp(a), lipoprotein (a);
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk study;
WOSCOPS, West of Scotland Coronary Prevention study.
a Values of Lp(a) concentration were winsorized at 130mg/dL.
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outcome association for log-transformed CHD risk was ap-
proximately linear, ie, fixed changes in absoluteLp(a) concen-
trations led to equal odds ratios (ORs) for CHD regardless of
the starting Lp(a) concentration (Figure 2A). By contrast, the
exposure–outcome association for deciles of log-trans-
formed Lp(a) concentrationwas curvilinear (Figure 2B), with
fixed proportional changes in Lp(a) concentrations leading to
greater log-ORs for individualswithhigher baselineLp(a) con-
centrations (andhence, increasingly greater absolute changes
inLp[a] concentrations).These findingsareconsistentandsup-
port thehypothesis that the risk of CHD is log-linearly propor-
tional to absolute changes in Lp(a) concentration.
Overall, each 10-mg/dL lower genetically predicted Lp(a)
levelwas associatedwith a 5.8% lower risk ofCHD (OR,0.942;
95% CI, 0.933-0.951; P = 3 × 10−37). There was no evidence of
heterogeneity with similar genetic association estimates ob-
tained across all studies independent of the type of Lp(a) as-
sayused (eFigures6 and7 in theSupplement). Estimateswere
also similar in sensitivity analyses that varied the number of
genetic variants included in the LPA score (eTable 4 in the
Supplement). In external replication analyses involving par-
ticipants from CARDIOGRAMplusC4D, a 10-mg/dL lower
genetically predicted Lp(a) level was associated with a 5.2%
lower risk of CHD (OR, 0.948; 95% CI, 0.941-0.955;
P = 1 × 10−47).
Expected Clinical Benefit of Lowering Lp(a) Concentration
Using the LDL-C genetic score, a 10-mg/dL genetically pre-
dicted lower LDL-C level was associated with a 14.5% lower
risk of CHD (OR, 0.855; 95% CI, 0.818-0.893; P = 2 × 10−12)
(eFigure 8 in the Supplement). This finding suggests that a
1-mg/dLdifference inLDL-C levelhas thesameassociationwith
CHD risk as a 2.63-mg/dL difference in Lp(a) concentration
(ie, log[0.855] / log[0.942] = 2.63), and therefore, a 38.67-
mg/dL difference in LDL-C level has the same association
as a 101.5-mg/dL (95% CI, 71.0-137.0) difference in Lp(a) con-
centration. In external replication analyses using data from
CARDIOGRAMplusC4D, a 10-mg/dL lower LDL-C level was as-
sociatedwitha14.0%lowerCHDrisk (OR,0.860;95%CI,0.841-
0.879; P = 3 × 10−40), suggesting that a 109.1-mg/dL (95%
CI, 89.0-133.1) difference in Lp(a) concentration has the same
associationwithCHDriskasa38.67-mg/dLdifference inLDL-C
level.
Changes in genetically predictedLp(a) andLDL-C concen-
trations represent lifelong exposure to these lipoproteins.
Hence, to estimate the effect of lowering Lp(a) concentration
in a short-term trial, we assumed that if lifelong exposure to
101.5-mg/dL lower Lp(a) concentration has the same associa-
tionwith CHD risk as lifelong exposure to 38.67-mg/dL lower
LDL-C level, then short-term exposure to 101.5-mg/dL lower
Lp(a)concentrationshouldhavethesameassociationwithCHD
risk as short-term exposure to 38.67-mg/dL lower LDL-C lev-
elsobserved in randomizedtrials.Thisassumption isvalidonly
if changes in Lp(a) concentration and LDL-C level have simi-
lar cumulative associations with CHD over time. It is further
supported by the observation that the ratio of the association
of lifelong exposure to Lp(a) with CHD risk estimated from
mendelian randomization to the association of intermediate-
term exposure to Lp(a), estimated from observational stud-
ies in the Emerging Risk Factors Consortium,2 is very similar
to the ratioof theassociationof lifelongexposure toLDL-Cwith
CHD risk estimated frommendelian randomization to the as-
sociation of intermediate-term exposure to LDL-C in the
Emerging Risk Factors Consortium (Figure 3; eFigure 9 in the
Figure 1. Association of LPAVariantsWith Lipoprotein(a) (Lp[a]) Concentration
and Coronary Heart Disease (CHD) Risk
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Supplement).25 Therefore, Lp(a) and LDL-C appear to have
similar cumulativeassociationswith the riskofCHDover time.
Table2showstheexpectedclinicalbenefit inCHDrisk from
both lifelong and short-term exposure to absolute differ-
ences in Lp(a) concentration. Lifelong estimates are conven-
tional mendelian randomization estimates, while short-term
estimates are calculated using the difference in Lp(a) concen-
tration needed to achieve the same change for a given reduc-
tion in LDL-C level over amedian of 5 years of treatmentwith
a statin, as reported by the Cholesterol Treatment Trialists’
Collaboration.18
Independent Association of Lp(a)
and LDL-C–Lowering Therapies
Toassesswhether theassociationof loweringLp(a) concentra-
tion with the risk of CHD is likely to be independent of lower-
ing LDL-C level with statins, we divided the population into 3
groupsbasedonthenumberofLDL-C–loweringalleleseachpar-
ticipant inherited at a common variant (rs12916) in the 3-hy-
droxy-3-methyl-glutaryl-CoAreductase (HMGCR) gene,which
encodesthetargetofstatins.26,27TheLPAscorehadnearly iden-
ticalassociationsper10-mg/dLlowerLp(a)concentrationineach
of these3groups (CCgenotypegroup:OR,0.945;95%CI,0.927-
0.964;CTgenotypegroup:OR,0.939;95%CI,0.927-0.952;TT
genotypegroup:OR,0.945;95%CI,0.932-0.957;P = .79 fordif-
ference) (eFigure10intheSupplement), suggestingthattherela-
tive risk reduction of lowering Lp(a) concentration is likely to
be independent of lowering LDL-C level with statins. Similar
findings were observed for genetic variants in the PCSK9 and
NPC1L1 gene regions that mimic the changes associated with
PCSK9 inhibitors and ezetimibe, respectively.
Discussion
Wefound that the associationof genetically predictedplasma
Lp(a)with the risk of CHDwas linearly proportional to the ab-
solute difference in Lp(a) concentration. Absolute differ-
ences in Lp(a) concentrationof approximately 100mg/dLhad
an equivalent associationwith CHD risk as a 38.67-mg/dLdif-
ference in LDL-C level. The results of this studymay have im-
portant implications for informing clinical practice guide-
lines on the use of Lp(a)-lowering therapies, for designing
randomized trials to evaluate Lp(a)-lowering therapies cur-
rently in development, and for designing screening programs
to reduce the global burden of CHD.
Becausea100-mg/dLdifference inLp(a) concentrationhad
the same association with CHD risk as a 38.67-mg/dL differ-
ence inLDL-C level, the results of this study suggest that phar-
macologically lowering Lp(a) concentration by approxi-
mately 100mg/dL should reduce the risk of CHD (CHD death
or nonfatal myocardial infarction) by approximately 22% to
25% in a 3- to 5-year randomized trial, similar to the associa-
tion that has been observed for a 38.67-mg/dL reduction in
Figure 2. Shape of Association Between Genetically Predicted Lipoprotein(a) (Lp[a]) and Coronary Heart Disease (CHD) Risk
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LDL-C level during treatment with a statin.17-19 Therefore, it
follows that lowering Lp(a) concentration by 80mg/dLmight
be expected to reduce the risk of CHD events by approxi-
mately 18% to 20%,while lowering Lp(a) concentration by 50
mg/dLmight reduce CHD events by 10% to 12% (Table 2), as-
suming that there are no unrecognized competing risks asso-
ciatedwith loweringLp(a) concentration.Therefore, onlyper-
sons with very high Lp(a) concentrations are likely to benefit
substantially from therapies that reduce Lp(a) concentration.
This finding likely explains why therapies that reduce
Lp(a) concentration by 20% to 35% have failed to provide
clear evidence that lowering Lp(a) concentration reduces
the risk of cardiovascular events in previous randomized
trials even though Lp(a) is a genetically supported target.
The median Lp(a) concentration among participants
enrolled in these trials was approximately 12 to 20
mg/dL.7-11 Therefore, a 30% reduction in Lp(a) concentra-
tion would translate into only a 3- to 6-mg/dL absolute
reduction in circulating plasma Lp(a) concentration, a small
absolute reduction that was likely far too modest to reduce
the risk of cardiovascular events appreciably in a short-term
randomized trial.
Table 2. Expected Clinical Benefit of Lowering Lp(a)
Reduction in Lp(a) Concentration,
mg/dL
Reduction in LDL-C Level for
Equivalent CHD Risk Reduction,
mg/dL (95% CI)a
Estimated Lifelong Proportional Risk
Reduction Owing to Genetically Decreased
Exposure, % (95% CI)b
Estimated Short-term Proportional Risk
Reduction in Randomized Trial, % (95%
CI)c
120 45.7 (34.1-65.4) 51.1 (45.5-56.2) 27.7 (20.9-37.5)
100 38.1 (28.4-54.5) 44.9 (39.7-49.8) 23.7 (17.8-32.4)
80 30.5 (22.7-43.6) 38.0 (33.2-42.3) 19.4 (14.5-26.9)
50 19.0 (14.2-27.3) 25.8 (22.3-29.1) 12.6 (9.3-17.8)
30 11.4 (8.5-16.4) 16.4 (14.1-18.7) 7.8 (5.7-11.1)
20 7.6 (5.7-10.9) 11.3 (9.6-12.9) 5.3 (3.8-7.5)
10 3.8 (2.8-5.5) 5.8 (4.9-6.7) 2.7 (1.9-3.9)
5 1.9 (1.4-2.7) 2.9 (2.5-3.4) 1.3 (1.0-1.9)
Abbreviations: CHD, coronary heart disease; LDL-C, low-density lipoprotein
cholesterol; Lp(a), lipoprotein (a).
SI conversion factor: To convert LDL-C tomillimoles per liter, multiply by
0.0259.
a Eachmg/dL lower Lp(a) has an association with CHD risk that is equivalent to a
0.38-mg/dL reduction in LDL-C based on the ratio of the associations of the
genetic scores with CHD risk.
b Effect size (95% confidence interval) for Lp(a) reduction obtained from
mendelian randomization approach.
c Effect size (95% confidence interval) for Lp(a) reduction obtained by
considering equivalent lowering of LDL-C and in comparison with estimate
from randomized trials of statins onmajor coronary events (risk ratio, 0.76;
95% CI, 0.73-0.78).
Figure 3. Estimates of Coronary Heart Disease (CHD) Risk ReductionWith Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Level
and Lipoprotein(a) (Lp[a]) Concentration
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The results of this study suggest that randomized trials
evaluating new, more potent Lp(a)-lowering therapies in de-
velopment should bedesigned to enroll individualswith very
highbaselineLp(a) concentrationsof90 to 100mg/dLormore.
Reducing Lp(a) concentration by 80% to 90% in such indi-
viduals should translate into largeabsolute reductions inLp(a)
concentrations of 70 to90mg/dL,which should in turn trans-
late into approximately a 15% to 20% proportional reduction
in the riskofCHDevents. Enrollingpatients athigh riskofCHD
owing tomarkedly elevated Lp(a) concentration in the initial
proof-of-concept clinical trials is similar to the strategy used
by the ScandinavianSimvastatin Survival Study trial,28which
enrolledhigh-riskpatientswithmarkedlyelevatedLDL-Ccon-
centrations and was the first trial to demonstrate that treat-
ment with statins led to large, clinically meaningful reduc-
tions in the risk of cardiovascular events.
The magnitude of the pharmacologic reduction in Lp(a)
mass that is likelyneeded toproduce clinicallymeaningful re-
ductions in CHD risk estimated in this study is larger than es-
timated in a 2018 study evaluating changes in Lp(a) during
treatmentwithniacin.29However,whereas thatpreviousstudy
involved informal estimates of the reversibleCHD risk by low-
ering Lp(a) concentrations in a short-term trial,29 we used a
more systematic approach. In particular, our study estimated
the differences in genetically predicted Lp(a) and LDL-C con-
centrations needed to have the same change in lifetime CHD
risk and incorporated an assessment of thedifferential cumu-
lative associations of Lp(a) andLDL-CwithCHD risk over time
to estimate how much Lp(a) concentration must be lowered
pharmacologically to produce the same change as lowering
LDL-C level by 38.67 mg/dL (ie, 1 mmol/L) with a statin. This
approach has been successfully used to accurately anticipate
the results of several recent trials.26,27,30 Similar analyses to
those used in the current study are needed before it would be
possible to accurately anticipate the potential effect of phar-
macologically lowering Lp(a) on the risk of stroke, peripheral
vascular disease, aortic stenosis, or composite endpoints that
include these outcomes.31
Finally, it should be noted that plasma Lp(a) concentra-
tion is largelyheritable.Therefore, if the linear relationshipwith
CHD risk continues at very high absolute Lp(a) concentra-
tions (as occurs for LDL-C), then Lp(a) concentrations in ex-
cess of 200 mg/dL may be associated with a 3- to 4-fold in-
creased lifetime risk of CHD (OR, 3.30; 95%CI, 2.75-3.96) and
thusmay represent an inherited lipoproteindisorder that is as-
sociated with a similar lifetime risk of CHD as heterozygous
familial hypercholesterolemia butwith aprevalence thatmay
be 2-fold higher than that of heterozygous familial
hypercholesterolemia.32,33 Therefore, screening for individu-
als with extremely elevated Lp(a) concentrations and treat-
ing themwith one of the new Lp(a)-lowering therapies in de-
velopment couldpotentially have the sameeffect on reducing
the global burden of CHD as current screening programs de-
signed to detect and treat individualswith familial hypercho-
lesterolemia.
Limitations
Our studyhas limitations.Multiple different assayswereused
tomeasureLp(a) concentrations in the included studies.How-
ever, we focused only on absolute differences in Lp(a) associ-
ated with genetic variants, which were very similar across all
includedstudies, regardlessofassayusedorbaselineLp(a) con-
centrations. In addition, our estimate of the effect of lowering
Lp(a) is agnostic to themechanismofaction, andhenceouruse
of plasma Lp(a) mass concentration to estimate the dose-
response relationship does not imply that our estimates are
solelyvia changes inplasmaLp(a)mass concentration. If phar-
macologicLp(a) loweringhas associationsnot adequately cap-
turedby thegeneticvariants (eg, antithrombotic associations),
then smaller absolute reductions in Lp(a) than estimatedhere
may produce clinicallymeaningful reductions in CHD risk.34
Conclusions
The association of genetically predicted Lp(a) with CHD risk
was linearly proportional to the absolute change inLp(a)mass
concentration. Large absolute reductions in Lp(a) concentra-
tionofapproximately 100mg/dLare likelynecessary toachieve
clinically meaningful reductions in the risk of CHD similar in
magnitude to what can be achieved by lowering LDL-C level
by 38.67 mg/dL (ie, 1 mmol/L) with a statin.
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